Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease
- PMID: 10025423
- DOI: 10.1001/archneur.56.2.179
Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease
Abstract
Background: Parkinson disease (PD) is associated with a progressive loss of nigrostriatal dopamine neurons. Medication therapy provides adequate control of symptoms for several years, but long-term treatment is complicated by progressive disability and the development of motor fluctuations and dyskinesias. In animal models of PD, fetal nigral transplants have been shown to survive grafting into the striatum, provide extensive striatal reinnervation, and improve motor function. In patients with PD, cell survival and clinical benefit have been observed following fetal nigral grafting, but results have been inconsistent.
Objective: To evaluate the safety and efficacy of bilateral fetal nigral transplantation into the postcommissural putamen in patients with advanced PD complicated by motor fluctuations and dyskinesias.
Patients and methods: Six patients with advanced PD underwent bilateral fetal nigral transplantation. Each patient received solid grafts derived from donors aged 6 1/2 to 9 weeks after conception stereotactically implanted into the postcommissural putamen using 3 to 4 donors per side. Cyclosporine was administered for approximately 6 months to provide immune suppression. Clinical evaluations included the Unified Parkinson's Disease Rating Scale (UPDRS), Schwab-England Activities of Daily Living Scale, and timed tests of motor function conducted during both the "off' and "on" states at baseline and at 1, 3, 6, 9, 12, 18, and 24 months following transplantation. Percentage of time off and percentage of time on with and without dyskinesia were recorded at half-hour intervals using home diaries during the week prior to each evaluation. 18F-fluorodopa positron emission tomographic scans were performed at baseline, and at 6 months and 1 year following transplantation.
Results: Patients have been followed up for a mean+/-SD of 20.5+/-5.5 months. Complications related to surgery were mild and transient. Activities of daily living, motor, and total (activities of daily living plus motor) UPDRS scores during the off state improved significantly (P<.05, Wilcoxon signed rank test) at final visit in comparison with baseline. Mean total UPDRS off score improved 32%, and each patient experienced at least a 19% improvement. Mean percentage of time on without dyskinesia during the waking day improved from 22% to 60% (P<.05). Mean putamenal fluorodopa uptake on positron emission tomography increased significantly at 6 and 12 months in comparison with baseline (P<.001, 2-tailed t test). This increase correlated with clinical improvement. Two patients died 18 months after transplantation from causes unrelated to the surgical procedure. In both cases, histopathological examination showed robust survival of tyrosine hydroxylase immunoreactive cells and abundant reinnervation of the postcommissural putamen.
Conclusions: Fetal nigral tissue can be transplanted into the postcommissural putamen bilaterally in patients with advanced PD safely and with little morbidity. In this open-label pilot study we observed consistent long-term clinical benefit and increased fluorodopa uptake on positron emission tomography. Clinical improvement appears to be related to the survival and function of transplanted fetal tissue.
Similar articles
-
Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease.Mov Disord. 1998 May;13(3):383-93. doi: 10.1002/mds.870130303. Mov Disord. 1998. PMID: 9613726
-
Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's disease.Ann Neurol. 1995 Sep;38(3):379-88. doi: 10.1002/ana.410380307. Ann Neurol. 1995. PMID: 7668823
-
Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease.N Engl J Med. 1995 Apr 27;332(17):1118-24. doi: 10.1056/NEJM199504273321702. N Engl J Med. 1995. PMID: 7700284
-
Fetal nigral transplantation as a therapy for Parkinson's disease.Trends Neurosci. 1996 Mar;19(3):102-9. doi: 10.1016/s0166-2236(96)80038-5. Trends Neurosci. 1996. PMID: 9054056 Review.
-
Bilateral contemporaneous posteroventral pallidotomy for the treatment of Parkinson's disease: neuropsychological and neurological side effects. Report of four cases and review of the literature.J Neurosurg. 1999 Aug;91(2):313-21. doi: 10.3171/jns.1999.91.2.0313. J Neurosurg. 1999. PMID: 10433321 Review.
Cited by
-
Cell therapy for neurological disorders.Nat Med. 2024 Oct;30(10):2756-2770. doi: 10.1038/s41591-024-03281-3. Epub 2024 Oct 15. Nat Med. 2024. PMID: 39407034 Review.
-
Cell replacement therapy in neurological disease.Philos Trans R Soc Lond B Biol Sci. 2006 Sep 29;361(1473):1463-75. doi: 10.1098/rstb.2006.1886. Philos Trans R Soc Lond B Biol Sci. 2006. PMID: 16939969 Free PMC article. Review.
-
Overcoming Methodological Challenges for Advancing Stem Cell Therapies in Parkinson's Disease.Cell Transplant. 2024 Jan-Dec;33:9636897241246355. doi: 10.1177/09636897241246355. Cell Transplant. 2024. PMID: 38634440 Free PMC article. Review.
-
Intermittent, low dose carbon monoxide exposure enhances survival and dopaminergic differentiation of human neural stem cells.PLoS One. 2018 Jan 16;13(1):e0191207. doi: 10.1371/journal.pone.0191207. eCollection 2018. PLoS One. 2018. PMID: 29338033 Free PMC article.
-
Transplantation of human neural progenitor cells secreting GDNF into the spinal cord of patients with ALS: a phase 1/2a trial.Nat Med. 2022 Sep;28(9):1813-1822. doi: 10.1038/s41591-022-01956-3. Epub 2022 Sep 5. Nat Med. 2022. PMID: 36064599 Free PMC article. Clinical Trial.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical